Akoya Biosciences (AKYA) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was $16.6M, down 9–9.8% year-over-year, with a net loss of $15.7M, improved from $23.5M in Q1 2024.

• Gross margin rose to 59–59.3% from 45.7–46% year-over-year, driven by lower costs and discontinued legacy products.

• Operating expenses decreased 22–22.3% year-over-year, reflecting workforce reductions and facility consolidation.

• The company entered into a merger agreement with Quanterix, expected to close in Q2 2025, with integration aimed at value creation in precision medicine.

• There is substantial doubt about the company's ability to continue as a going concern if the merger is not completed.

Financial highlights

• Product revenue was $12.0M; service and other revenue was $4.6M for Q1 2025.

• Gross profit increased to $9.9M from $8.4M year-over-year.

• Operating loss improved to $13.4M from $21.6M year-over-year.

• Cash, cash equivalents, and marketable securities totaled $27.5M as of March 31, 2025.

• Net cash used in operating activities was $7.2M, a significant improvement from $20.8M in Q1 2024.

Outlook and guidance

• The merger with Quanterix is expected to close in Q2 2025, subject to customary conditions.

• If the merger is not consummated, the company may not maintain compliance with debt covenants and may need to seek waivers or refinancing.

• Management plans to focus on growth, operational improvements, and achieving cash flow positivity.

• No forward-looking guidance provided due to the pending acquisition.